Receptor tyrosine kinase inhibitors

¹Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA. adjei.alex@mayo.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|January 31, 2002

Summary

Receptor tyrosine kinases (RTKs) are crucial for cell growth but drive cancer. Small-molecule RTK antagonists targeting growth factor pathways are in clinical trials for cancer treatment.

Area of Science:

Molecular Biology
Oncology
Pharmacology

Background:

Receptor tyrosine kinases (RTKs) are transmembrane proteins vital for cellular functions like growth and angiogenesis.
Aberrant RTK signaling pathways are frequently implicated in cancer development, promoting tumor growth and metastasis.

Purpose of the Study:

To discuss the biology of RTKs in malignancies.
To review clinical trial results of small-molecule RTK antagonists.

Main Methods:

Review of scientific literature on RTK biology and cancer.
Analysis of clinical trial data for RTK inhibitors.

Main Results:

RTKs play a significant role in oncogenic activation, tumor angiogenesis, and mitogenic stimulation.
Numerous small-molecule RTK antagonists targeting EGF, VEGF, PDGF, and FGF receptors are in various clinical development phases.

Conclusions:

RTKs are critical targets for novel anticancer drug development.
Small-molecule antagonists show promise in inhibiting key cancer-driving pathways.

Related Experiment Videos

Receptor tyrosine kinase inhibitors

Related Concept Videos

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors.

Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.

Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey.

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Control of Intraocular Metastases of ALK-Rearranged Non-Small Cell Lung Cancer with Sequential Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Report of 2 Cases and Review of the Literature.

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.

Hierarchical ROS-scavenging hydrogel system for coordinating the modulation of RGC necroptosis and oxidative stress in an acute glaucoma model.

Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?

Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.

Related Experiment Videos

Receptor tyrosine kinase inhibitors

Area of Science:

Background:

Purpose of the Study:

Main Methods:

Main Results:

Conclusions:

Related Concept Videos

Related Articles